In summary, IL-23 has been identified as a key factor in activating the IL-17/NF-κB inflammatory signaling axis and has been confirmed as a key target for XTS to exert its anti-inflammatory effects in synovial inflammation in RA. The gene discussed is IL17A; the disease is inflammation.